A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease

  • Sparrow, Miles (Primary Chief Investigator (PCI))
  • Croft, Anthony (Partner Investigator (PI))
  • Leong, Rupert Wing Loong (Partner Investigator (PI))
  • Moore, Gregory (Partner Investigator (PI))

Project: Research

Project Details

StatusActive
Effective start/end date22/10/24 → 12/09/28

Keywords

  • clinical trial
  • Crohn’s Disease
  • Tulisokibart